Skip to Content

Tivozanib (Fotivda) for Relapsed or Refractory Advanced Renal Cell Carcinoma

Download PQI pdf 0.25MB

Last Updated: September 9, 2025

By: Pedro C. Barata, MD

About this PQI

The purpose of this PQI is to review the clinical considerations around the use of tivozanib (Fotivda®) for patients with relapsed or refractory advanced renal cell carcinoma.

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI